MaMome is an emerging biotech company on a mission to become the leading AI-based testing platform for microbiome-based maternal health management and pregnancy complication prevention. MaMome is the pioneer brand in monitoring and improving fetal-maternal and infant health based on the early identification of high-risk pregnancies based on the bacterial composition of the maternal microbiome. Using proprietary next-generation genomic sequencing and machine learning, MaMome will enable earlier clinical interventions, change the standard of care for at-risk patients, and increase the potential of healthcare equity.